186 related articles for article (PubMed ID: 32988968)
21. Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients.
Delgado-Ureña M; Ortega FG; de Miguel-Pérez D; Rodriguez-Martínez A; García-Puche JL; Ilyine H; Lorente JA; Exposito-Hernandez J; Garrido-Navas MC; Delgado-Ramirez M; Serrano MJ
J Transl Med; 2018 Sep; 16(1):251. PubMed ID: 30189880
[TBL] [Abstract][Full Text] [Related]
22. Panitumumab: a review of its use in metastatic colorectal cancer.
Keating GM
Drugs; 2010 May; 70(8):1059-78. PubMed ID: 20481659
[TBL] [Abstract][Full Text] [Related]
23. Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study.
Claret L; Pentafragka C; Karovic S; Zhao B; Schwartz LH; Maitland ML; Bruno R
Cancer Chemother Pharmacol; 2018 Jul; 82(1):49-54. PubMed ID: 29700575
[TBL] [Abstract][Full Text] [Related]
24. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C
Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946
[TBL] [Abstract][Full Text] [Related]
25. Semiautomated volumetric response evaluation as an imaging biomarker in superior sulcus tumors.
Vos CG; Dahele M; van Sörnsen de Koste JR; Senan S; Bahce I; Paul MA; Thunnissen E; Smit EF; Hartemink KJ
Strahlenther Onkol; 2014 Feb; 190(2):204-9. PubMed ID: 24362500
[TBL] [Abstract][Full Text] [Related]
26. Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials.
Hirose K; Oki E; Shimose T; Sakamoto S; Sasaki S; Jogo T; Hu Q; Tsuda Y; Ando K; Nakashima Y; Saeki H; Mori M
Int J Clin Oncol; 2019 Nov; 24(11):1397-1405. PubMed ID: 31332611
[TBL] [Abstract][Full Text] [Related]
27. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
[TBL] [Abstract][Full Text] [Related]
28. Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.
Manca P; Corallo S; Randon G; Lonardi S; Cremolini C; Rimassa L; Bergamo F; Antoniotti C; Smiroldo V; Zaniboni A; Murialdo R; Tampellini M; Tomasello G; Clavarezza M; Racca P; Antista M; Raimondi A; Prisciandaro M; Pagani F; Palermo F; Greco FG; Vaiani M; Di Bartolomeo M; de Braud F; Calareso G; Morano F; Pietrantonio F
Eur J Cancer; 2021 Feb; 144():31-40. PubMed ID: 33321462
[TBL] [Abstract][Full Text] [Related]
29. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
[TBL] [Abstract][Full Text] [Related]
30. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study.
Werner-Wasik M; Xiao Y; Pequignot E; Curran WJ; Hauck W
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):56-61. PubMed ID: 11516851
[TBL] [Abstract][Full Text] [Related]
31. Dynamic volume perfusion computed tomography parameters versus RECIST for the prediction of outcome in lung cancer patients treated with conventional chemotherapy.
Sudarski S; Shi J; Schmid-Bindert G; Manegold C; Pilz LR; Zhou C; Schoenberg SO; Henzler T
J Thorac Oncol; 2015 Jan; 10(1):164-71. PubMed ID: 25247342
[TBL] [Abstract][Full Text] [Related]
32. Spotlight on panitumumab in metastatic colorectal cancer.
Keating GM
BioDrugs; 2010 Aug; 24(4):275-8. PubMed ID: 20623992
[TBL] [Abstract][Full Text] [Related]
33. Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.
Engelmann BE; Loft A; Kjær A; Nielsen HJ; Gerds TA; Benzon EV; Brünner N; Christensen IJ; Hansson SH; Holländer NH; Kristensen MH; Löfgren J; Markova E; Sloth C; Højgaard L
Oncologist; 2014 Feb; 19(2):164-72. PubMed ID: 24451199
[TBL] [Abstract][Full Text] [Related]
34. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
Degirmencioglu S; Tanriverdi O; Menekse S; Dogan M; Hacıoglu B; Oktay E; Erdem D; Arpaci E; Uluc BO; Turhal S; Yilmaz M; Pilanci KN; Sakin A; Araz M; Cokmert S; Ozdemir O; Sen E; Nayir E
J BUON; 2019; 24(1):136-142. PubMed ID: 30941962
[TBL] [Abstract][Full Text] [Related]
35. Target lesion selection: an important factor causing variability of response classification in the Response Evaluation Criteria for Solid Tumors 1.1.
Keil S; Barabasch A; Dirrichs T; Bruners P; Hansen NL; Bieling HB; Brümmendorf TH; Kuhl CK
Invest Radiol; 2014 Aug; 49(8):509-17. PubMed ID: 24651664
[TBL] [Abstract][Full Text] [Related]
36. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis.
Chen Q; Cheng M; Wang Z; Zhao S
Medicine (Baltimore); 2016 Dec; 95(50):e5284. PubMed ID: 27977573
[TBL] [Abstract][Full Text] [Related]
38. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
Liang RF; Zheng LL
Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the agreement between tumour volumetry and the estimated volumes of tumour lesions using an algorithm.
Laubender RP; Lynghjem J; D'Anastasi M; Heinemann V; Modest DP; Mansmann UR; Sartorius U; Schlichting M; Graser A
Eur Radiol; 2014 Jul; 24(7):1521-8. PubMed ID: 24816938
[TBL] [Abstract][Full Text] [Related]
40. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.
Hendlisz A; Golfinopoulos V; Garcia C; Covas A; Emonts P; Ameye L; Paesmans M; Deleporte A; Machiels G; Toussaint E; Vanderlinden B; Awada A; Piccart M; Flamen P
Ann Oncol; 2012 Jul; 23(7):1687-93. PubMed ID: 22112970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
